J. O’Donnell

发表

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases

S. McLeod, R. Tommasi, M. Sacco, 2020, Journal of medicinal chemistry.

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

D. Ehmann, S. McLeod, Camilo Velez-Vega, 2017, Nature Microbiology.

Effect of Linezolid on the 50% Lethal Dose and 50% Protective Dose in Treatment of Infections by Gram-Negative Pathogens in Naive and Immunosuppressed Mice and on the Efficacy of Ciprofloxacin in an Acute Murine Model of Septicemia

I. Medina, A. Marra, Joel R. Hardink, 2012, Antimicrobial Agents and Chemotherapy.

In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species

J. Lipuma, R. Panchal, K. Papp-Wallace, 2020, Antimicrobial Agents and Chemotherapy.

Single-dose Pharmacokinetics , Excretion , and Metabolism of Zoliflodacin , a 1 Novel Spiropyrimidinetrione Antibiotic , in Healthy Volunteers 2

K. Vishwanathan, J. O’Donnell, John P. Mueller, 2018 .

Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols.

T. Gootz, M. Huband, S. J. Brickner, 2011, ACS medicinal chemistry letters.

Zoliflodacin: An oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrhoeae, including multi-drug resistant isolates.

P. Bradford, Alita A. Miller, J. O’Donnell, 2020, ACS infectious diseases.

Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections.

Bryan M. Li, T. Dougherty, R. Obach, 2009, Journal of medicinal chemistry.

Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects

R. Isaacs, K. Rodvold, M. Gotfried, 2018, Antimicrobial Agents and Chemotherapy.

Agents by Pseudomonas aeruginosa Siderophore-Conjugated Antibacterial Adaptation-Based Resistance to

P. Tomaras, J. Crandon, C. McPherson, 2014 .

N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.

R. Tommasi, M. Sacco, April Chen, 2020, Bioorganic & medicinal chemistry.

Rational design of a new antibiotic class for drug-resistant infections

S. McLeod, A. Ferguson, G. Drusano, 2021, Nature.

Biopharmaceutical-Based Pharmacokinetic Modeling of Sulopenem Prodrugs: Impact of Luminal Stability on Fraction of Dose Absorbed

S. Sutton, T. Gootz, A. Marfat, 2003 .

Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.

A. Eakin, Renu Singh, P. Bradford, 2015, The Journal of antimicrobial chemotherapy.

Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the β-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282

Angela Tanudra, R. Tommasi, April Chen, 2020, ACS infectious diseases.

LpxC Inhibitors as New Antibacterial Agents and Tools for Studying Regulation of Lipid A Biosynthesis in Gram-Negative Pathogens

M. Kuhn, Tess M. Eidem, Alita A. Miller, 2014, mBio.

Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.

V. Shanmugasundaram, K. Leach, M. Huband, 2012, Journal of medicinal chemistry.

Potent inhibitors of LpxC for the treatment of Gram-negative infections.

V. Shanmugasundaram, J. Warmus, K. Leach, 2012, Journal of medicinal chemistry.

Translating slow-binding inhibition kinetics into cellular and in vivo effects.

Peter J Tonge, Virna J A Schuck, Zhiping You, 2015, Nature chemical biology.

Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent

S. Richter, R. Bonomo, K. Hujer, 2019, mBio.

Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea - challenges and opportunities.

M. Unemo, F. Franceschi, G. Drusano, 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Clinically Relevant Gram-Negative Resistance Mechanisms Have No Effect on the Efficacy of MC-1, a Novel Siderophore-Conjugated Monocarbam

L. Aschenbrenner, C. McPherson, M. Lemmon, 2012, Antimicrobial Agents and Chemotherapy.

Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers

K. Vishwanathan, V. Hosagrahara, J. O’Donnell, 2018, Antimicrobial Agents and Chemotherapy.

Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.

V. Shanmugasundaram, Ye Che, J. Chen, 2012, Bioorganic & medicinal chemistry letters.

Adaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by Pseudomonas aeruginosa

D. Nicolau, J. Crandon, C. McPherson, 2013, Antimicrobial Agents and Chemotherapy.

11-Ketotigogenin cellobioside (pamaqueside): a potent cholesterol absorption inhibitor in the hamster.

R. Wilkins, M. Deninno, S. W. Walinsky, 1996, Journal of Medicinal Chemistry.

Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.

Bryan M. Li, A. Stepan, J. Aubrecht, 2013, Journal of medicinal chemistry.

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

R. Isaacs, Alita A. Miller, R. Fomkin, 2019, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects

R. Preston, R. Isaacs, J. O’Donnell, 2019, Antimicrobial Agents and Chemotherapy.

The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex

S. Bhavnani, J. O’Donnell, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects

R. Isaacs, J. O’Donnell, K. Lawrence, 2020, Antimicrobial Agents and Chemotherapy.